Moderna has announced positive results from its late-stage trial of an mRNA-based flu vaccine, called mRNA-1010. The data shows that the vaccine produced a stronger immune response than a currently available shot for the virus, paving the way for Moderna to apply for approval of its standalone flu vaccine later this year.
The company’s combination jab targeting Covid-19 and influenza is also expected to be resubmitted for approval after the new data. If regulators approve the flu vaccine, Moderna plans to advance the combination shot next year, pending reviews.
The phase three trial involved over 40,000 adults aged 50 and above, who received a single dose of mRNA-1010 or a standard competitor vaccine. The results showed that Moderna’s shot was 26.6% more effective than the other vaccine in the overall study population, with strong efficacy for each major influenza strain.
The mRNA-1010 jab demonstrated consistent benefits across different age groups, people with various risk factors, and previous vaccination status against the flu. In adults aged 65 and older, the shot was 27.4% more effective than the standard flu vaccine.
Moderna’s CEO, Stephane Bancel, hailed the results as a “significant milestone” in reducing the burden of influenza in older adults. The company is now poised to advance its combination Covid-19 and flu jab after previously withdrawing an application due to regulatory concerns.
Source: https://www.cnbc.com/2025/06/30/modernas-flu-vaccine-shows-positive-trial-results-paving-way-for-combo-shot.html